Role of histone deacetylase on nonalcoholic fatty liver disease

References

• Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8(Suppl 1):S4–8.
   PubMedGoogle Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatol. 2016 Jul;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation. Liver Transpl. 2018 Feb;24(2):166–170.
   PubMed Web of Science ®Google Scholar
• Cholankeril G, Wong RJ, Hu M, et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci. 2017 Oct;62(10):2915–2922.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019 Mar;17(4):748–755.e3.
   PubMed Web of Science ®Google Scholar
• Golabi P, Bush H, Stepanova M, et al. Liver transplantation (LT) for cryptogenic cirrhosis (CC) and nonalcoholic steatohepatitis (NASH) cirrhosis: data from the scientific registry of transplant recipients (SRTR): 1994 to 2016. Med (Baltimore). 2018 Aug;97(31):e11518.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11–20.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatol. 2016 Nov;64(5):1577–1586.
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020 Jul;73(1):202–209.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatol. 2018 Jan;67(1):328–357.
   PubMed Web of Science ®Google Scholar
• Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harbor Perspect Biol. 2014 Apr 1; 6(4):a018713.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Wen Y, Liang B, et al. Gene expression profile-based drug screen identifies SAHA as a novel treatment for NAFLD. Mol Omics. 2019 Feb 11;15(1):50–58.
   PubMed Web of Science ®Google Scholar
• Rui L. Energy metabolism in the liver. Compr Physiol. 2014 Jan;4(1):177–197.
   PubMed Web of Science ®Google Scholar
• Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation. 2019 Jan;103(1):e1–e13.
   PubMed Web of Science ®Google Scholar
• Fazel Y, Koenig AB, Sayiner M, et al. Epidemiology and natural history of non-alcoholic fatty liver disease. Metab. 2016 Aug;65(8):1017–1025.
   PubMed Web of Science ®Google Scholar
• McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015 May;62(5):1148–1155.
   PubMed Web of Science ®Google Scholar
• Hu X, Huang Y, Bao Z, et al. Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterol. 2012 Sep 14;12:123.
   PubMed Web of Science ®Google Scholar
• Chan WK, Treeprasertsuk S, Imajo K, et al. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. Aliment Pharmacol Ther. 2018 Mar;47(6):816–825.
   PubMed Web of Science ®Google Scholar
• Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015 Apr;13(4):643–54.e1-9; quiz e39–40.
   Web of Science ®Google Scholar
• Sayiner M, Koenig A, Henry L, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. 2016 May;20(2):205–214.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatol. 2019 Jun;69(6):2672–2682.
   PubMed Web of Science ®Google Scholar
• Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatol. 2010 May;51(5):1593–1602.
   PubMed Web of Science ®Google Scholar
• Dassanayake AS, Kasturiratne A, Rajindrajith S, et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol. 2009 Jul;24(7):1284–1288.
   PubMed Web of Science ®Google Scholar
• Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019 May;4(5):389–398.
   PubMed Web of Science ®Google Scholar
• Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 Aug;34(3):274–285.
   PubMed Web of Science ®Google Scholar
• Inoue A, Fujimoto D. Enzymatic deacetylation of histone. Biochem Biophys Res Commun. 1969 Jul 07;36(1):146–150. 1969.
   PubMed Web of Science ®Google Scholar
• Garcia-Ramirez M, Rocchini C, Ausio J. Modulation of chromatin folding by histone acetylation. J Biol Chem. 1995 Jul 28;270(30):17923–17928.
   PubMed Web of Science ®Google Scholar
• Tse C, Sera T, Wolffe AP, et al. Disruption of higher-order folding by core histone acetylation dramatically enhances transcription of nucleosomal arrays by RNA polymerase III. Mol Cell Biol. 1998 Aug;;18(8):4629–4638.
   PubMed Web of Science ®Google Scholar
• Wang X, Hayes JJ. Acetylation mimics within individual core histone tail domains indicate distinct roles in regulating the stability of higher-order chromatin structure. Mol Cell Biol. 2008 Jan;28(1):227–236.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zang C, Cui K, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009 Sep 4;138(5):1019–1031.
   PubMed Web of Science ®Google Scholar
• Liu Y, Jiang L, Sun C, et al. Insulin/Snail1 axis ameliorates fatty liver disease by epigenetically suppressing lipogenesis. Nat Commun. 2018 Jul 16;9(1):2751.
   PubMedGoogle Scholar
• Kojima T, Takano K, Yamamoto T, et al. Transforming growth factor-beta induces epithelial to mesenchymal transition by down-regulation of claudin-1 expression and the fence function in adult rat hepatocytes. Liver Int. 2008 Apr;28(4):534–545.
   PubMed Web of Science ®Google Scholar
• Yook JI, Li XY, Ota I, et al. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol. 2006 Dec;8(12):1398–1406.
   PubMed Web of Science ®Google Scholar
• Kaimori A, Potter J, Kaimori JY, et al. Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem. 2007 Jul 27;282(30):22089–22101.
   PubMed Web of Science ®Google Scholar
• Abiola M, Favier M, Christodoulou-Vafeiadou E, et al. Activation of Wnt/beta-catenin signaling increases insulin sensitivity through a reciprocal regulation of Wnt10b and SREBP-1c in skeletal muscle cells. PLoS One. 2009 Dec 30;4(12):e8509.
   PubMed Web of Science ®Google Scholar
• McNairn AJ, Doucet Y, Demaude J, et al. TGFβ signaling regulates lipogenesis in human sebaceous glands cells. BMC Dermatol. 2013 Jan 23;13:2.
   PubMedGoogle Scholar
• Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009 May 26;2(72):re3.
   PubMed Web of Science ®Google Scholar
• Miquilena-Colina ME, Lima-Cabello E, Sánchez-Campos S, et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut. 2011 Oct;60(10):1394–1402.
   PubMed Web of Science ®Google Scholar
• Bieghs V, Wouters K, van Gorp PJ, et al. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterol. 2010 Jun;138(7):2477–86, 2486.e1–3.
   PubMed Web of Science ®Google Scholar
• Zhong S, Zhao L, Wang Y, et al. Cluster of differentiation 36 deficiency aggravates macrophage infiltration and hepatic inflammation by upregulating monocyte chemotactic protein-1 expression of hepatocytes through histone deacetylase 2-Dependent pathway. Antioxid Redox Signal. 2017 Aug 1;27(4):201–214.
   PubMed Web of Science ®Google Scholar
• Berthiaume M, Boufaied N, Moisan A, et al. High levels of oxidative stress globally inhibit gene transcription and histone acetylation. DNA Cell Biol. 2006 Feb;25(2):124–134.
   PubMed Web of Science ®Google Scholar
• Baeck C, Wehr A, Karlmark KR, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut. 2012 Mar;61(3):416–426.
   PubMed Web of Science ®Google Scholar
• Singha B, Gatla HR, Vancurova I. Transcriptional regulation of chemokine expression in ovarian cancer. Biomol. 2015 Mar 17;5(1):223–243.
   Google Scholar
• Janabi M, Yamashita S, Hirano K, et al. Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):1953–1960.
   PubMed Web of Science ®Google Scholar
• Sun Z, Miller RA, Patel RT, et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat Med. 2012 Jun;18(6):934–942.
   PubMed Web of Science ®Google Scholar
• Papazyan R, Sun Z, Kim YH, et al. Physiological suppression of lipotoxic liver damage by complementary actions of HDAC3 and SCAP/SREBP. Cell Metab. 2016 Dec 13;24(6):863–874.
   PubMed Web of Science ®Google Scholar
• Liang N, Jakobsson T, Fan R, et al. The nuclear receptor-co-repressor complex in control of liver metabolism and disease. Front Endocrinol (Lausanne). 2019;10:411.
   PubMed Web of Science ®Google Scholar
• Guenther MG, Lane WS, Fischle W, et al. A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev. 2000 May 1;14(9):1048–1057.
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Wang J, et al. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. Embo J. 2000 Aug 15;19(16):4342–4350.
   PubMed Web of Science ®Google Scholar
• Zhang J, Kalkum M, Chait BT, et al. The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol Cell. 2002 Mar;9(3):611–623.
   PubMed Web of Science ®Google Scholar
• Oberoi J, Fairall L, Watson PJ, et al. Structural basis for the assembly of the SMRT/NCoR core transcriptional repression machinery. Nat Struct Mol Biol. 2011 Feb;18(2):177–184.
   PubMed Web of Science ®Google Scholar
• Sommars MA, Ramachandran K, Senagolage MD, et al. Dynamic repression by BCL6 controls the genome-wide liver response to fasting and steatosis. Elife. 2019 Apr 15;8:e43922.
   Web of Science ®Google Scholar
• Balasubramanian S, Ramos J, Luo W, et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 2008 May;22(5):1026–1034.
   PubMed Web of Science ®Google Scholar
• Vannini A, Volpari C, Filocamo G, et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. PNAS. 2004 Oct 19;101(42):15064–15069.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Nakayama T, Arao T, et al. SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma. Blood. 2013 May 2;121(18):3640–3649.
   PubMed Web of Science ®Google Scholar
• Wu J, Du C, Lv Z, et al. The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma. Dig Dis Sci. 2013 Dec;58(12):3545–3553.
   PubMed Web of Science ®Google Scholar
• Tian Y, Wong VW, Wong GL, et al. Histone deacetylase HDAC8 promotes insulin resistance and β-catenin activation in NAFLD-associated hepatocellular carcinoma. Cancer Res. 2015 Nov 15;75(22):4803–4816.
   PubMed Web of Science ®Google Scholar
• Jukes TH, Williams WL. Nutritional effects of antibiotics. Pharmacol Rev. 1953;5(4):381–420. 1953.
   PubMed Web of Science ®Google Scholar
• Taylor JH, Gordon WS. Growth-promoting activity for pigs of inactivated penicillin. Nature. 1955 Aug 13;176(4476):312–313.
   PubMed Web of Science ®Google Scholar
• Coates ME, Fuller R, Harrison GF, et al. A comparison of the growth of chicks in the Gustafsson germ-free apparatus and in a conventional environment, with and without dietary supplements of penicillin. Br J Nutr. 1963;17:141–150.
   PubMed Web of Science ®Google Scholar
• Forbes M, Park JT. Growth of germ-free and conventional chicks: effect of diet, dietary penicillin and bacterial environment. J Nutr. 1959 Jan 10;67(1):69–84.
   PubMed Web of Science ®Google Scholar
• Lieber AD, Beier UH, Xiao H, et al. Loss of HDAC6 alters gut microbiota and worsens obesity. FASEB. 2019 Jan;33(1):1098–1109.
   PubMed Web of Science ®Google Scholar
• de Carvalho SC, Muniz MT, Siqueira MD, et al. Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). Nutr J. 2013 Apr 2;12:37.
   PubMed Web of Science ®Google Scholar
• Kalhan SC, Guo L, Edmison J, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metab. 2011 Mar;60(3):404–413.
   PubMed Web of Science ®Google Scholar
• Liang H, Xie X, Song X, et al. Orphan nuclear receptor NR4A1 suppresses hyperhomocysteinemia-induced hepatic steatosis in vitro and in vivo. FEBS Lett. 2019 May;593(10):1061–1071.
   PubMed Web of Science ®Google Scholar
• Maxwell MA, Muscat GE. The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nucl Recept Signal. 2006;4:e002.
   PubMedGoogle Scholar
• Zhao Y, Bruemmer D. NR4A orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology. Arterioscler Thromb Vasc Biol. 2010 Aug;30(8):1535–1541.
   PubMed Web of Science ®Google Scholar
• Wu T, Liu YH, Fu YC, et al. Direct evidence of sirtuin downregulation in the liver of non-alcoholic fatty liver disease patients. Annals Clin Lab Sci. 2014 Fall.;44(4):410–418.
   PubMed Web of Science ®Google Scholar
• Bruce KD, Szczepankiewicz D, Sihota KK, et al. Altered cellular redox status, sirtuin abundance and clock gene expression in a mouse model of developmentally primed NASH. BBA. 2016 Jul;1861(7):584–593.
   PubMed Web of Science ®Google Scholar
• Geng C, Zhang Y, Gao Y, et al. Mst1 regulates hepatic lipid metabolism by inhibiting Sirt1 ubiquitination in mice. Biochem Biophys Res Commun. 2016 Mar 18;471(4):444–449.
   PubMed Web of Science ®Google Scholar
• Tobita T, Guzman-Lepe J, Takeishi K, et al. SIRT1 disruption in human fetal hepatocytes leads to increased accumulation of glucose and lipids. PLoS One. 2016;11(2):e0149344.
   PubMed Web of Science ®Google Scholar
• Mariani S, Fiore D, Basciani S, et al. Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients. Endocrine. 2015 Aug;49(3):711–716.
   PubMed Web of Science ®Google Scholar
• Purushotham A, Schug TT, Xu Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009 Apr;9(4):327–338.
   PubMed Web of Science ®Google Scholar
• Kim KE, Kim H, Heo RW, et al. Myeloid-specific SIRT1 deletion aggravates hepatic inflammation and steatosis in high-fat diet-fed mice. Korean J Physiol Pharmacol. 2015 Sep;19(5):451–460.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Horváth B, Rajesh M, et al. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis. J Hepatol. 2017 Mar;66(3):589–600.
   PubMed Web of Science ®Google Scholar
• Zhang W, Sun Y, Liu W, et al. SIRT1 mediates the role of RNA-binding protein QKI 5 in the synthesis of triglycerides in non-alcoholic fatty liver disease mice via the PPARα/FoxO1 signaling pathway. Int J Mol Med. 2019 Mar;43(3):1271–1280.
   PubMed Web of Science ®Google Scholar
• Li Y, Xu S, Giles A, et al. Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. Faseb J. 2011 May;25(5):1664–1679.
   PubMed Web of Science ®Google Scholar
• Colak Y, Yesil A, Mutlu HH, et al. A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. JGLD. 2014 Sep;23(3):311–319.
   PubMed Web of Science ®Google Scholar
• Nogueiras R, Habegger KM, Chaudhary N, et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012 Jul;92(3):1479–1514.
   PubMed Web of Science ®Google Scholar
• Shimazu T, Hirschey MD, Hua L, et al. SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab. 2010 Dec 1;12(6):654–661.
   PubMed Web of Science ®Google Scholar
• Hebert AS, Dittenhafer-Reed KE, Yu W, et al. Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol Cell. 2013 Jan 10;49(1):186–199.
   PubMed Web of Science ®Google Scholar
• Hirschey MD, Shimazu T, Goetzman E, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010 Mar 4;464(7285):121–125.
   PubMed Web of Science ®Google Scholar
• Osborne B, Montgomery M, Reznick J, et al. Effect of acute hepatic overexpression of SIRT3 on metabolic parameters in short-term high fat fed mice. Diabetologia. 2012;55:S263–S263.
   Web of Science ®Google Scholar
• Kendrick AA, Choudhury M, Rahman SM, et al. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J. 2011 Feb 1;433(3):505–514.
   PubMed Web of Science ®Google Scholar
• Finley LW, Haas W, Desquiret-Dumas V, et al. Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity. PLoS One. 2011;6(8):e23295.
   PubMed Web of Science ®Google Scholar
• Cimen H, Han MJ, Yang Y, et al. Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochem. 2010 Jan 19;49(2):304–311.
   PubMed Web of Science ®Google Scholar
• Zeng X, Yang J, Hu O, et al. Dihydromyricetin ameliorates nonalcoholic fatty liver disease by improving mitochondrial respiratory capacity and redox homeostasis through modulation of SIRT3 signaling. Antioxid Redox Signal. 2019 Jan 10;30(2):163–183.
   PubMed Web of Science ®Google Scholar
• Li R, Xin T, Li D, et al. Therapeutic effect of Sirtuin 3 on ameliorating nonalcoholic fatty liver disease: the role of the ERK-CREB pathway and Bnip3-mediated mitophagy. Redox Biol. 2018;18:229–243.
   PubMed Web of Science ®Google Scholar
• Li S, Dou X, Ning H, et al. Sirtuin 3 acts as a negative regulator of autophagy dictating hepatocyte susceptibility to lipotoxicity. Hepatol. 2017 Sep;66(3):936–952.
   PubMed Web of Science ®Google Scholar
• Fernandez-Marcos PJ, Jeninga EH, Canto C, et al. Muscle or liver-specific Sirt3 deficiency induces hyperacetylation of mitochondrial proteins without affecting global metabolic homeostasis. Sci Rep. 2012;2:425.
   PubMed Web of Science ®Google Scholar
• Bagchi RA, Ferguson BS, Stratton MS, et al. HDAC11 suppresses the thermogenic program of adipose tissue via BRD2. JCI Insight. 2018 Aug 9;3:15.
   Web of Science ®Google Scholar
• Sun L, Marin de Evsikova C, Bian K, et al. Programming and regulation of metabolic homeostasis by HDAC11. EBioMed. 2018;33:157–168.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metab. 2016 Aug;65(8):1062–1079.
   PubMed Web of Science ®Google Scholar
• Shimizu A, Takamura T, Matsuzawa N, et al. Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. Metab. 2007 Nov;56(11):1478–1485.
   PubMed Web of Science ®Google Scholar
• Adolph TE, Grander C, Grabherr F, et al. Adipokines and non-alcoholic fatty liver disease: multiple Interactions. Int J Mol Sci. 2017 Jul 29;18(8):1649.
   PubMed Web of Science ®Google Scholar
• Nassir F, Ibdah JA. Sirtuins and nonalcoholic fatty liver disease. World J Gastroenterol. 2016 Dec 14; 22(46):10084–10092.
   PubMed Web of Science ®Google Scholar
• Huber Y, Boyle M, Hallsworth K, et al. Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Clin Gastroenterol Hepatol. 2019 Sep;17(10):2085–2092.e1.
   PubMed Web of Science ®Google Scholar
• Lagger G, O’Carroll D, Rembold M, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. Embo J. 2002 Jun 3;21(11):2672–2681.
   PubMed Web of Science ®Google Scholar
• Montgomery RL, Potthoff MJ, Haberland M, et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest. 2008 Nov;118(11):3588–3597.
   PubMed Web of Science ®Google Scholar
• Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nat. 2003 Sep 11;425(6954):191–196.
   Google Scholar
• Asghari S, Asghari-Jafarabadi M, Somi MH, et al. Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum sirtuin-1 levels in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Am Coll Nutr. 2018 Mar-Apr;37(3):223–233.
   PubMed Web of Science ®Google Scholar
• Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005 May;115(5):1343–1351.
   PubMed Web of Science ®Google Scholar